Specific Immune Responses and Oncolytic Effects Induced by EBV LMP2A-Armed Modified Ankara-Vaccinia Virus Vectored Vaccines in Nasopharyngeal Cancer.

ABSTRACT:

Background

The Epstein-Barr virus (EBV) is intricately linked to a range of human malignancies, with EBV latent membrane protein 2A (LMP2A) emerging as a potential target antigen for immunotherapeutic strategies in the treatment of nasopharyngeal carcinoma (NPC).

Methods

The modified vaccinia virus Ankara (MVA) is universally used in vector vaccine research because of its excellent safety profile and highly efficient recombinant gene expression. Here, we constructed a novel MVA-LMP2A recombinant virus and investigated its specific immune response induction and oncolytic effect.

Results

An immunization dose of 2 × 10⁷ PFU induced the highest specific immune response, which was no longer increased by boost injections after four doses. Three weeks post-final i

SUBMITTER: Sun L 

PROVIDER: S-EPMC11768126 | biostudies-literature | 2025 Jan

REPOSITORIES: biostudies-literature